2. Signaling Pathways
  3. Immunology/Inflammation
  4. Galectin

Galectin

Galectin

Related Products

PDF 0.13 MB

Galectins comprise a family of soluble β-galactoside binding proteins, which regulate key biological processes including cell growth, differentiation, apoptosis, and immune responses.

Sixteen galectin genes have been identified in animal kingdoms, 12 of which are expressed in humans. Galectins are usually classified into three groups based on their structure: (i) prototypical galectins (galectin-1 (Gal1), Gal2, Gal5, Gal7, Gal10, Gal11, Gal 13, Gal14, and Gal15), characterized by a single CRD, which can act as monomers or form homodimers; (ii) the chimeric galectin Gal3 (the only member of this class), with a single CRD and a large amino-terminal domain that facilitates the formation of oligomers; (iii) the tandem repeat galectins, with two CRDs that are linked through a small peptide domain; this group includes Gal4, Gal6, Gal8, Gal9, and Gal12. Recently, Galectins have been implicated as major therapeutic determinants that confer sensitivity or resistance to a wide range of anticancer modalities including chemotherapy, radiotherapy, targeted therapies, antiangiogenic therapies, and immunotherapies.

Galectin Isoform Specific Products:

Galectin Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P992366
    HFB200901
    		Inhibitor
    HFB200901 is a galectin LGALS9 inhibitor and immunostimulant that can be used in studies related to pancreatic adenocarcinoma, pancreatic intraepithelial neoplasia, KRASG12C-mutant colon cancer, and prostate cancer. HFB200901 disrupts the LGALS9/TIM-3 axis, while blocking the internalization and vacuolization of recombinant LGALS9. HFB200901 reduces the proportion of regulatory T cells (Treg) and enhances dendritic cell activation, thereby inducing polyfunctional and memory CD8+ T cell responses. HFB200901 inhibits the progression of pancreatic neoplastic lesions and effectively improves the efficacy of PSMA-based vaccination.
    HFB200901
  • HY-144313
    Galectin-3-IN-2
    		Inhibitor
    Galectin-3-IN-2 (Compound 9) is a potent multivalent inhibitor of galectin-3 (Gal-3; IC50=8.3 μM). Galectin-3 participates in many cancer-related metabolic processes.
    Galectin-3-IN-2
  • HY-173235
    Galectin-3-IN-6
    		Inhibitor
    Galectin-3-IN-6 is a human and murine galectin-3 (Gal-3) inhibitor, with an IC50 of 12 nM against human galectin-3, an IC50 of 12.6 nM against mutant murine galectin-3 (V160A), and a Kd of 13 nM for human galectin-3, as well as oral bioavailability. Galectin-3-IN-6 reduces the levels of liver fibrosis markers type I collagen and α-smooth muscle actin in mouse models of acute liver injury and fibrosis. Galectin-3-IN-6 can be used for the research of acute liver injury and fibrosis.
    Galectin-3-IN-6
  • HY-123708
    SNAP 398299
    		Antagonist
    SNAP 398299 is a Gal3 receptor antagonist with potential anxiolytic and antidepressant effects. SNAP 398299 can partially reverse the neuropeptide Galanin-induced inhibition of dorsal raphe cell firing and the Galanin-induced hyperpolarizing current.
    SNAP 398299
  • HY-146809
    Galectin-3 antagonist 2
    Galectin-3 is a β Galactoside specific carbohydrate recognition protein (lectin) has the ability to promote the migration of B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells and withstand drug research.
    Galectin-3 antagonist 2
  • HY-163405
    Galectin-3-IN-3
    		Inhibitor
    Galectin-3-IN-3 (Compound 4) is an orally active and selective inhibitor of Gal-3, with IC50 values of 11 nM and 84 nM against mGal-3 and hGal-3 respectively.
    Galectin-3-IN-3
  • HY-180937
    CHI3L1-IN-6
    		Inhibitor
    CHI3L1-IN-6 (Compound 9e) is a CHI3L1 inhibitor with a Kd of 19.11 μM for hCHI3L1. CHI3L1-IN-6 blocks CHI3L1-Galectin-3 interaction. CHI3L1-IN-6 reduces STAT3 signaling. CHI3L1-IN-6 exhibits anti-cancer activity against glioblastoma.
    CHI3L1-IN-6
  • HY-176259
    F3-PEG8-RiboTAC
    		Degrader
    F3-PEG8-RiboTAC is a RiboTAC that can specifically degrade the mRNA of the oncogene LGALS1. F3-PEG8-RiboTAC can induce tumor cell apoptosis and inhibit invasion. F3-PEG8-RiboTAC has anti-tumor activity and can be used in the research of tumors such as leukemia and triple-negative breast cancer. (RNase L ligand (HY-177030); RNA binder (HY-177031); Linker (HY-W019798)).
    F3-PEG8-RiboTAC
  • HY-162789
    Galectin-3-IN-5
    		Inhibitor
    Galectin-3-IN-5 (Compound 20) is an orally active inhibitor of galectin-3 (Gal-3), with an IC50 value of 9.2 nM against hGal-3.
    Galectin-3-IN-5
  • HY-163900
    Galectin-8N-IN-2
    		Inhibitor
    Galectin-8N-IN-2 (compound 2) is a potent and selective Galectin-8N inhibitor with a Ki value of 74 μM.
    Galectin-8N-IN-2
  • HY-N16021
    4A-MPLA ammonium
    		Activator
    4A-MPLA ammonium is an orally active TLR4 agonist. 4A-MPLA ammonium induces TLR4 endocytosis dependent on Cdc42 and galectin-3, triggering TRIF-mediated signaling and sustained IFN-β production. 4A-MPLA ammonium promotes lipid droplet formation, upregulates interferon-stimulated genes and type I IFN signaling genes, downregulates lysosome/phagosome function genes, and modulates tolerogenic dendritic cell function. 4A-MPLA ammonium can be used for the research of colitis.
    4A-MPLA ammonium
Cat. No. Product Name / Synonyms Application Reactivity
Galectin Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.